OncoMatch/Clinical Trials/NCT06562920
Adebrelimab Combined With Chemotherapy and Concurrent SBRT for Neoadjuvant Treatment of Limited-stage Small Cell Lung Cancer
Is NCT06562920 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies adebrelimab and chemotherapy for efficacy and safety of neoadjuvant immunotherapy for small cell lung cancer.
Treatment: adebrelimab and chemotherapy — To explore the effectiveness and safety of adebrelimab combined with chemotherapy and concurrent SBRT for 3 cycles of neoadjuvant treatment followed by surgery in T1-3N0-1M0 limited-stage SCLC
Check if I qualifyExtracted eligibility criteria
Cancer type
Small Cell Lung Cancer
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: anti-tumor treatment
No previous anti-tumor treatment such as surgery, radiotherapy, chemotherapy, immunotherapy, etc. related to small cell lung cancer
Cannot have received: immune checkpoint inhibitor (PD-1 inhibitor, PD-L1 inhibitor)
Previously used immune checkpoint inhibitors such as PD-1/PD-L1 inhibitors
Cannot have received: anti-tumor vaccine or immunostimulatory therapy (interferon, interleukin, thymosin, immune cell therapy)
Subjects who have been treated with anti-tumor vaccines or other anti-tumor drugs with immunostimulatory effects (interferon, interleukin, thymosin, immune cell therapy, etc.) within 1 month before the first medication
Lab requirements
Blood counts
ANC ≥1.5×10^9/L, platelets ≥100×10^9/L, hemoglobin ≥9 g/dl
Kidney function
serum creatinine ≤1.25x ULN or creatinine clearance ≥60 ml/min
Liver function
total bilirubin ≤1.5x ULN, AST and ALT ≤2.5x ULN
Cardiac function
LVEF ≥55%, no clear signs of heart failure, severe coronary artery stenosis, etc.; able to tolerate surgical treatment
Patients must have sufficient cardiopulmonary function: FEV1 and DLCO of patients are ≥50% of the predicted value, echocardiography indicates LVEF ≥55%, and no clear signs of heart failure, severe coronary artery stenosis, etc. are found in various tests. Cardiopulmonary function is assessed by surgeons to be able to tolerate surgical treatment; ...Bone marrow: absolute neutrophil count (ANC) ≥1.5× 10^9/L, platelets ≥100 × 10^9/L, hemoglobin ≥9 g/dl; ...Liver: total bilirubin ≤1.5 times the upper limit of normal, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5 times the upper limit of normal; ...Kidney: serum creatinine ≤1.25 times the upper limit of normal or creatinine clearance (calculated by Cockcroft-Gault formula) ≥60 ml/min
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify